Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)

NCT01023477 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Intraductal, Noninfiltrating
DCIS
Ductal Carcinoma In Situ

Interventions

DRUG: Chloroquine Standard Dose (500mg/week)
DRUG: Chloroquine Low Dose (250mg/week)
PROCEDURE: Breast Biopsy

Sponsor

Inova Health Care Services

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]